Skip to main content

Table 2 Comparison of regression and recurrence rate between patients with retinopathy of prematurity received intravitreal Bevacizumab (IVB) and intravitreal Aflibercept (IVA)

From: Comparison of aflibercept and bevacizumab in the treatment of type 1 retinopathy of prematurity

Parameter Level Total Type of treatment p‡
IVB IVA
Regression Number (%) 854 (96.1%) 830 (96.0%) 24 (100.0%) 0.023
Estimated Median (days) (95% CI)†   10.0 (9.2 to 10.8) 14.0 (9.2 to 18.8)  
Mean observed time (days) ± SD ¥   14 ± 10 22 ± 15  
Median observed time (days) (range) ¥   10 (1 to 64) 16 (6 to 57)  
Recurrence Number (%) 47 (5.5%) 34 (3.9%) 14 (58.3%)  < 0.001
Estimated Median (days) (95% CI)†   NA 96.0 (76.3 to 115.7)  
Mean observed time (days) ± SD ¥   47 104  
Median observed time (days) ¥   23 92  
  1. Based on log-rank test
  2. Estimated time to have 50% of participants in the group to have the outcomes
  3. ¥ Computed in the occurred participants